$ 1.2 billion ADC goes out to sea!What are the motivation for stone medicine growth in the critical period

$ 1.2 billion, ADC goes out to sea! In the critical period, what are the growth momentum of stone medicine?

Source: Yaizhi.com/clover

In summer, the sickle of the autumn harvest has been prepared. When the ADC innovation layout seems to have reached the "autumn harvest", the transaction cooperation has come frequently.

On July 28, the Stone Medicine Group authorized the Claudin 18.2adc to ElevationOncology for $ 1.195 billion.

According to the terms of the agreement, the stone medicine boulder biology agrees to award the exclusive authorization of EleviceOncology to develop and commercialize the product in the region. Stone medicine boulder creatures will charge $ 27 million in down payment, and have the right to collect potential development and regulatory milestones with a maximum of $ 148 million and the potential sales milestone payment of up to $ 1.02 billion.

Stone medicine boulder biology also has the right to collect a sales commission with a net annual sales of the product in the region of the region. Stone medicine boulder creatures will retain all rights of the product in Greater China.

Joint development has become a trend. At the time of going to sea?

It is worth noting that this is the second in the week of this week's antibody coupling (ADC) drugs (ADC) drugs authorized development. On July 26, Coron Pharmaceuticals once again joined for more than $ 900 million to join forces Merhado to exclusively authorize an ADC cooperation development right.

According to incomplete statistics from public information, ADC biological similar drugs are removed, and there are 14 new ADC drugs in the world, of which 4 have been listed in China. The new domestic ADC drug, the Vidici monocity of the Rongchang creature alone; however, in recent years, the rapid development of the ADC field has set off the heating of ADC research and development in China. As of now, about 60 ADC drugs are under research.

And with the popularity of ADC drugs and the increasing competition pattern, and more and more new ADC new drugs have been listed one after another; in order to maximize the power of ADC and the rapid realization of commercial value, joint development has become a trend.

According to statistics, there are currently nearly 30 cooperation transactions reached by ADC drugs around the world, including 18 of Chinese pharmaceutical companies. It is worth mentioning that in the past years, in order to enhance its own R & D strength and enrich R & D pipeline, various enterprises have continuously introduced products from the outside to the inside.

Entering 2022, ADC drugs seem to open the door to the sea, and continue from inside to License-OUT. Among the seven projects, including Shi Pharmaceutical Group and Coron Pharmaceutical, six have reached transaction cooperation this year, and have been completed in recent months. According to the layout of the domestic ADC new drugs and the inside of the innovative drug competition pattern, more and more ADC new drugs will go to sea. At this moment, the SYSA1801 overseas authorization or justice of the Stone Medicine Group.

Domestic AdcliceNSEOUT details

Data source: Public information finishing

Lock the return in advance to enhance competitiveness

Return to the SYSA1801 drug itself, whether or not to go to the sea to seek cooperation; the tumor therapy company Elevation is bought at a high price of 1.2 billion US dollars. The competitive potential and market prospects are evident.

Public information shows that the Sysa1801 of the Stone Medicine Group, as a CLAUDIN18.2adc, is a considerable track in the field of ADC research. Claudin18.2 is often expressed in gastric cancer, pancreatic cancer, and lung cancer, and is generally generally expressed in other types of cancer. In normal tissue, Claudin18.2 is strictly limited to the differential epithelial cells that are usually buried in gastric mucosa, and basically cannot be touched by monoclonal antibodies. These mechanisms make Claudin18.2 a target of attractive and prospects.

At present, the major domestic pharmaceutical companies have more than 50 target drugs for Claudin18.2. Among them, 7 companies have the layout of the ADC, including the stone medicine and the Coron Group. Claudin18.2adc, Claudin18.2Adc, has completed overseas licensing. It is reported that according to the Colom pipeline speculation, the high probability of ADC drugs authorized by Merhado on July 26 is the new drug SKB315 and Claudin18.2ADC drugs.

Some domestic Claudin18.2-ADC is studying drugs

Figure source: "15 billion transactions! Can the big infusion faucet rely on the ADC counterattack? "

And this time the Claudin18.2ADC and Elevation have reached a cooperation. For stone medicine, on the one hand, it can lock the drug return income in advance and improve its competitiveness; on the other hand , To "go global", grow from traditional pharmaceutical companies to lay a solid foundation for BIGPHARM.

Cross -border and going to the sea; what other growth momentum does the Stone Medicine Group have?

As we all know, the Stone Medicine Group is one of the leading companies in the Chinese pharmaceutical industry with Hengrui Pharmaceutical and Fosun Pharmaceutical; but it is different from Hengrui Pharmaceutical and Fosun Pharmaceutical. It started with the drug medicine, which successfully transformed the production and increased the layout of R & D and innovation, and became a model of "independent innovation" in the same industry. And currently innovative drugs have become the main source of its corporate profits.

According to the financial report of Shi Pharmaceutical Group in 2021, in 2021, its R & D investment increased significantly again, exceeding 3 billion yuan for the first time, an increase of 18.8 % year -on -year %. At present, there are about 300 projects in the research projects, including more than 40 small molecular innovation medicines, more than 40 major molecular innovation medicines, and more than 30 new preparations. The field of vascular systems and anti -infective therapy; it is expected that there will be more than 30 innovative drugs and new preparation products in the next five years, as well as more than 60 generic drugs.

Picture source: corporate financial report

In addition, Cai Dongchen, chairman of the Shi Medicine Group, previously said that at present, the Shi Medicine Group is a critical period. Opening the road of internationalization is a problem that needs to be considered in the post -transformation era. There is no doubt that "research and development" and "internationalization" are the two flags of the Stone Medicine Group.

In terms of internationalization, in addition to SYSA1801 and August 2021, with the US Innovation Company Flamebiosciences, Inc. Establish a strategic cooperation and license agreement to award the candidate drug NBL-015 (anti-CLAUDIN18.2 single cloning antibody) and two models will be used. The new types of specific antibodies developed by the Group's NOVATE bilateral antibody technology platform are exclusive rights outside Greater China. There will also be CD20, CD47 dual -resistant platforms, and TNFR2 for overseas authorization, and have been negotiating; perhaps in the near future, there will be good news.

- END -